{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:13:25Z","timestamp":1793326405921,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018703","name":"HORIZON EUROPE European Innovation Council","doi-asserted-by":"publisher","award":["190120397"],"award-info":[{"award-number":["190120397"]}],"id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013297","name":"Eurostars","doi-asserted-by":"publisher","award":["9046-00177B"],"award-info":[{"award-number":["9046-00177B"]}],"id":[{"id":"10.13039\/100013297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013297","name":"Eurostars","doi-asserted-by":"publisher","award":["3150-00110B"],"award-info":[{"award-number":["3150-00110B"]}],"id":[{"id":"10.13039\/100013297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013297","name":"Eurostars","doi-asserted-by":"publisher","award":["3109-00046B"],"award-info":[{"award-number":["3109-00046B"]}],"id":[{"id":"10.13039\/100013297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["8064-00073B"],"award-info":[{"award-number":["8064-00073B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["0235-00009B"],"award-info":[{"award-number":["0235-00009B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["9065-00055B"],"award-info":[{"award-number":["9065-00055B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["0153-00195B"],"award-info":[{"award-number":["0153-00195B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["2040-00038B"],"award-info":[{"award-number":["2040-00038B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["0154-00017B"],"award-info":[{"award-number":["0154-00017B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["1045-00056B"],"award-info":[{"award-number":["1045-00056B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HERV-K (HML-2) is the most studied transcriptionally active endogenous retrovirus in human cancers, yet immune tolerance and incomplete mechanistic understanding have impeded its clinical use as an immunotherapy target. We hypothesized that rational engineering of the HERV-K envelope putative immunosuppressive domain (ISD) could improve immunogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a mutational screen across the ISD region, evaluated NF-\u03baB activation and then analyzed antigen expression in human monocyte-derived dendritic cells (moDCs) using flow cytometry, RNA-seq, and TEM. Human PBMCs were expanded with HERV-K\u2013transduced moDCs to assess T cell priming and expansion ex vivo. Immunogenicity was tested in mice, HERV-K transgenic mice, and cynomolgus macaques using adenoviral and LNP-mRNA vectors. Antitumor efficacy was evaluated in a murine metastatic renal carcinoma HERV-K expressing tumor model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Engineering the HERV-K envelope ISD to Q525A (ISDmut) enhanced NF-\u03baB activation, antigen expression, and antigen presentation and cell death associated gene expression pathways in human dendritic cells while preserving virus-like particle assembly. HERV-K-ISDmut-transduced human dendritic cells expanded CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells capable of recognizing HLA-matched, HERV-K expressing tumors, demonstrating that T cells from the human repertoire can be expanded ex vivo. In vivo, mRNA and adenoviral vectors encoding HERV-K-ISDmut elicited strong immune responses in mice, broke tolerance in HERV-K transgenic mice, and induced humoral responses in cynomolgus macaques. In mice, an adenovirus vectored HERV-K-ISDmut immunization further conferred increased survival in a murine renal carcinoma HERV-K expressing tumor model and benefitted from anti-PD-1 therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results show that the rational redesign of the HERV-K ISD generates a potent immunogen capable of expanding human T cells and mediating mechanistically relevant anti-tumor immunity. We propose that HERV-K-ISDmut antigens represent a promising platform for cancer immunotherapy which should be explored in future clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-09012-1","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:43:01Z","timestamp":1790264581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineering human endogenous retrovirus-K for improving immunogenicity and broad cancer targeting"],"prefix":"10.1186","volume":"24","author":[{"given":"Mikkel Dons","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Neukirch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Ragonnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia Vergara","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Daradoumis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Jaded","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie Sofie","family":"Engdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Faas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Perez-Penco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Picon-Jara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen N\u00f8rgaard","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Duvnjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte Rahbaek","family":"Boilesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Kusi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Skandorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna","family":"Skeltved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene Linh Ngoc","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaare Villum","family":"Grunddal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda Salahudin","family":"Darusman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silmi","family":"Mariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Schr\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer Staal","family":"Rohrberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik Otzen","family":"Bagger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thirion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Thor","family":"Straten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-4162","authenticated-orcid":false,"given":"Anne-Marie Carola","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Johannes","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"9012_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/S41568-022-00466-1","volume":"22","author":"CM Laumont","year":"2022","unstructured":"Laumont CM, Banville AC, Gilardi M, Hollern DP, Nelson BH. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer [Internet] Nat Res. 2022;22:414. https:\/\/doi.org\/10.1038\/S41568-022-00466-1. [cited 2026 Jun 2];.","journal-title":"Nat Rev Cancer [Internet] Nat Res"},{"key":"9012_CR2","doi-asserted-by":"publisher","unstructured":"Stein RA, Depaola RV. Human endogenous retroviruses: our genomic fossils and companions. Am Physiol Soc Rockv, MD; 2023;55:249\u201358. https:\/\/doi.org\/10.1152\/physiolgenomics001712022.","DOI":"10.1152\/physiolgenomics001712022"},{"key":"9012_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0248903","author":"BH Kang","year":"2021","unstructured":"Kang BH, Momin N, Moynihan KD, Silva M, Li Y, Irvine DJ, et al. Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice. PLoS One [Internet] PLoS One. 2021. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0248903. [cited 2026 Jun 3];16.","journal-title":"PLoS One [Internet] PLoS One"},{"key":"9012_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/V15040926","author":"J Daradoumis","year":"2023","unstructured":"Daradoumis J, Ragonnaud E, Skandorff I, Nielsen KN, Bermejo AV, Andersson AM, et al. An Endogenous Retrovirus Vaccine Encoding an Envelope with a Mutated Immunosuppressive Domain in Combination with Anti-PD1 Treatment Eradicates Established Tumours in Mice. Viruses [Internet] Viruses. 2023. https:\/\/doi.org\/10.3390\/V15040926. [cited 2026 May 11];15.","journal-title":"Viruses [Internet] Viruses"},{"key":"9012_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13100-020-00224-w","author":"MT Ueda","year":"2020","unstructured":"Ueda MT, Kryukov K, Mitsuhashi S, Mitsuhashi H, Imanishi T, Nakagawa S. Comprehensive genomic analysis reveals dynamic evolution of endogenous retroviruses that code for retroviral-like protein domains. Mob DNA [Internet]. 2020;11:29. https:\/\/doi.org\/10.1186\/s13100-020-00224-w."},{"key":"9012_CR6","doi-asserted-by":"publisher","unstructured":"Montserrat-Ayuso T, Esteve-Codina A. A Comprehensive annotation of conserved protein domains in human endogenous retroviruses [Internet]. 2025. https:\/\/doi.org\/10.1101\/2025.07.25.666750.","DOI":"10.1101\/2025.07.25.666750"},{"key":"9012_CR7","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3390\/ijms23031330","volume":"23","author":"MD M\u00fcller","year":"2022","unstructured":"M\u00fcller MD, Holst PJ, Nielsen KN. A Systematic Review of Expression and Immunogenicity of Human Endogenous Retroviral Proteins in Cancer and Discussion of Therapeutic Approaches. Int J Mol Sci [Internet]. 2022;23:1330. https:\/\/doi.org\/10.3390\/ijms23031330.","journal-title":"Int J Mol Sci [Internet]"},{"key":"9012_CR8","doi-asserted-by":"publisher","unstructured":"Stricker E, Peckham-Gregory EC, Scheurer ME, CancerHERVdb. Human endogenous retrovirus (HERV) Expression database for human cancer accelerates studies of the retrovirome and predictions for HERV-based therapies. Simon V, editor. J Virol [Internet]. 2023;97:e0005923. https:\/\/doi.org\/10.1128\/jvi.00059-23.","DOI":"10.1128\/jvi.00059-23"},{"key":"9012_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.cell.2025.01.046","volume":"188","author":"Q Jiang","year":"2025","unstructured":"Jiang Q, Braun DA, Clauser KR, Ramesh V, Shirole NH, Duke-Cohan JE, et al. HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. Cell [Internet]. 2025;188:1807\u2013e182734. https:\/\/doi.org\/10.1016\/j.cell.2025.01.046.","journal-title":"Cell [Internet]"},{"key":"9012_CR10","doi-asserted-by":"publisher","first-page":"e010099","DOI":"10.1136\/jitc-2024-010099","volume":"13","author":"P Bonaventura","year":"2025","unstructured":"Bonaventura P, Page A, Tabone O, Estornes Y, Mutez V, Delles M, et al. HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer. J Immunother Cancer [Internet]. 2025;13:e010099. https:\/\/doi.org\/10.1136\/jitc-2024-010099.","journal-title":"J Immunother Cancer [Internet]"},{"key":"9012_CR11","doi-asserted-by":"publisher","unstructured":"Kobayashi S, Tokita S, Moniwa K, Kitahara K, Iuchi H, Matsuo K, et al. Proteogenomic identification of an immunogenic antigen derived from human endogenous retrovirus in renal cell carcinoma. JCI Insight [Internet]. 2023;8. https:\/\/doi.org\/10.1172\/jci.insight.167712.","DOI":"10.1172\/jci.insight.167712"},{"key":"9012_CR12","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.18632\/oncotarget.26680","volume":"10","author":"L Neukirch","year":"2019","unstructured":"Neukirch L, Nielsen TK, Laursen H, Daradoumis J, Thirion C, Holst PJ. Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice. Oncotarget [Internet]. 2019;10:1458\u201372. https:\/\/doi.org\/10.18632\/oncotarget.26680.","journal-title":"Oncotarget [Internet]"},{"key":"9012_CR13","doi-asserted-by":"publisher","unstructured":"Skandorff I, Ragonnaud E, Gille J, Andersson AM, Schr\u00f6del S, Duvnjak L, et al. Human Ad19a\/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-cell response differences in inbred mice. Int J Mol Sci Multidisciplinary Digit Publishing Inst (MDPI). 2023;24. https:\/\/doi.org\/10.3390\/ijms24129972.","DOI":"10.3390\/ijms24129972"},{"key":"9012_CR14","doi-asserted-by":"publisher","first-page":"12507","DOI":"10.1128\/JVI.79.19.12507-12514.2005","volume":"79","author":"R Belshaw","year":"2005","unstructured":"Belshaw R, Dawson ALA, Woolven-Allen J, Redding J, Burt A, Tristem M. Genomewide screening reveals high levels of insertional polymorphism in the human endogenous retrovirus family HERV-K(HML2): implications for present-day activity. J Virol [Internet]. 2005;79:12507\u201314. https:\/\/doi.org\/10.1128\/JVI.79.19.12507-12514.2005.","journal-title":"J Virol [Internet]"},{"key":"9012_CR15","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/0008-5472.CAN-07-6838","volume":"68","author":"F Wang-Johanning","year":"2008","unstructured":"Wang-Johanning F, Radvanyi L, Rycaj K, Plummer JB, Yan P, Sastry KJ, et al. Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. Cancer Res [Internet]. 2008;68:5869\u201377. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6838.","journal-title":"Cancer Res [Internet]"},{"key":"9012_CR16","doi-asserted-by":"publisher","unstructured":"Attig J, Pape J, Doglio L, Kazachenka A, Ottina E, Young GR, et al. Human endogenous retrovirus onco-exaptation counters cancer cell senescence through calbindin. J Clin Invest [Internet]. 2023;133. https:\/\/doi.org\/10.1172\/JCI164397.","DOI":"10.1172\/JCI164397"},{"key":"9012_CR17","doi-asserted-by":"publisher","unstructured":"Nguyen QTT, Shin SG, Nguyen TTT, Lee KY, McClelland M, Lee EJ. Human endogenous retrovirus-K envelope protein is aberrantly expressed in serous ovarian cancer and promotes chemosensitivity via NF-\u03baB\/P-glycoprotein pathway inhibition. J Ovarian Res [Internet]. BioMed Central Ltd; 2025 [cited 2026 Jun 12];18:146. https:\/\/doi.org\/10.1186\/S13048-025-01722-2.","DOI":"10.1186\/S13048-025-01722-2"},{"key":"9012_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.clim.2018.03.007","volume":"191","author":"S Bahrami","year":"2018","unstructured":"Bahrami S, Gryz EA, Graversen JH, Troldborg A, Stengaard Pedersen K, Laska MJ. Immunomodulating peptides derived from different human endogenous retroviruses (HERVs) show dissimilar impact on pathogenesis of a multiple sclerosis animal disease model. Clin Immunol [Internet]. 2018;191:37\u201343. https:\/\/doi.org\/10.1016\/j.clim.2018.03.007.","journal-title":"Clin Immunol [Internet]"},{"key":"9012_CR19","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.annonc.2025.04.004","volume":"36","author":"L Belcaid","year":"2025","unstructured":"Belcaid L, H\u00f8jgaard M, Tuxen I, Spanggaard I, Lassen U, Robinson L, et al. Copenhagen Prospective Personalized Oncology (CoPPO)-impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting. Ann Oncol [Internet] Elsevier. 2025;36:1078\u201387. https:\/\/doi.org\/10.1016\/j.annonc.2025.04.004.","journal-title":"Ann Oncol [Internet] Elsevier"},{"key":"9012_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1742-4690-8-90","volume":"8","author":"RP Subramanian","year":"2011","unstructured":"Subramanian RP, Wildschutte JH, Russo C, Coffin JM. Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology [Internet]. 2011;8:90. https:\/\/doi.org\/10.1186\/1742-4690-8-90.","journal-title":"Retrovirology [Internet]"},{"key":"9012_CR21","doi-asserted-by":"publisher","DOI":"10.64898\/2026.02.17.706328","author":"T Montserrat-Ayuso","year":"2026","unstructured":"Montserrat-Ayuso T, Pujol A, Esteve-Codina A. Regulatory features and functional specialization of human endogenous retroviral LTRs: A genome-wide annotation and analysis via HERVarium. bioRxiv [Internet]. 2026;2026.02.17.706328. https:\/\/doi.org\/10.64898\/2026.02.17.706328."},{"key":"9012_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-62703-679-5_11","volume":"1089","author":"Z Ruzsics","year":"2014","unstructured":"Ruzsics Z, Lemnitzer F, Thirion C. Engineering adenovirus genome by bacterial artificial chromosome (BAC) technology. Methods Mol Biol [Internet]. 2014;1089:143\u201358. https:\/\/doi.org\/10.1007\/978-1-62703-679-5_11.","journal-title":"Methods Mol Biol [Internet]"},{"key":"9012_CR23","doi-asserted-by":"publisher","DOI":"10.1021\/ACSCHEMBIO.8B00061","author":"C Berg","year":"2018","unstructured":"Berg C, Daugvilaite V, Steen A, J\u00f8rgensen AS, V\u00e5ben\u00f8 J, Rosenkilde MM. Inhibition of HIV fusion by small molecule agonists through efficacy-engineering of CXCR4. ACS Chem Biol [Internet]. 2018 [cited 2026 Aug 23];13:881\u20136. https:\/\/doi.org\/10.1021\/ACSCHEMBIO.8B00061."},{"key":"9012_CR24","doi-asserted-by":"publisher","DOI":"10.3791\/50282","author":"JM Baker","year":"2014","unstructured":"Baker JM, Boyce FM. High-throughput Functional Screening using a Homemade Dual-glow Luciferase Assay. J Vis Exp [Internet] J Visualized Experiments. 2014. https:\/\/doi.org\/10.3791\/50282. [cited 2026 Aug 23];50282.","journal-title":"J Vis Exp [Internet] J Visualized Experiments"},{"key":"9012_CR25","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jim.2007.08.004","volume":"328","author":"T Kamala","year":"2007","unstructured":"Kamala T. Hock immunization: a humane alternative to mouse footpad injections. J Immunol Methods [Internet]. 2007;328:204\u201314. https:\/\/doi.org\/10.1016\/j.jim.2007.08.004.","journal-title":"J Immunol Methods [Internet]"},{"key":"9012_CR26","doi-asserted-by":"publisher","unstructured":"Lee YN, Bieniasz PD. Reconstitution of an infectious human endogenous retrovirus. Holmes EC, editor. PLoS Pathog [Internet]. 2007;3:e10. https:\/\/doi.org\/10.1371\/journal.ppat.0030010","DOI":"10.1371\/journal.ppat.0030010"},{"key":"9012_CR27","first-page":"3698","volume":"35","author":"P Janik","year":"1975","unstructured":"Janik P, Briand P, Hartmann NR. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res [Internet]. 1975;35:3698\u2013704. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1192428.","journal-title":"Cancer Res [Internet]"},{"key":"9012_CR28","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.3390\/cancers15245863","volume":"15","author":"J Daradoumis","year":"2023","unstructured":"Daradoumis J, M\u00fcller MD, Neckermann P, Asbach B, Schr\u00f6del S, Thirion C, et al. Preferential Expansion of HPV16 E1-Specific T Cells from Healthy Donors\u2019 PBMCs after Ex Vivo Immunization with an E1E2E6E7 Fusion Antigen. Cancers (Basel) [Internet]. 2023;15:5863. https:\/\/doi.org\/10.3390\/cancers15245863.","journal-title":"Cancers (Basel) [Internet]"},{"key":"9012_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/JNCI\/DJR540","volume":"104","author":"F Wang-Johanning","year":"2012","unstructured":"Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, Frerich K, et al. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst [Internet] J Natl Cancer Inst. 2012;104:189\u2013210. https:\/\/doi.org\/10.1093\/JNCI\/DJR540. [cited 2026 May 10];.","journal-title":"J Natl Cancer Inst [Internet] J Natl Cancer Inst"},{"key":"9012_CR30","doi-asserted-by":"publisher","unstructured":"Wei Y, Wei H, Wei Y, Tan A, Chen X, Liao X, et al. Screening and identification of human endogenous retrovirus-k mrnas for breast cancer through integrative analysis of multiple datasets. Front Oncol [Internet]. Frontiers Media S.A. 2022 [cited 2026 Aug 23];12:820883. https:\/\/doi.org\/10.3389\/FONC.2022.820883\/FULL.","DOI":"10.3389\/FONC.2022.820883\/FULL"},{"key":"9012_CR31","doi-asserted-by":"publisher","unstructured":"Morozov VA, Dao Thi VL, Denner J. The transmembrane protein of the human endogenous retrovirus\u2013K (HERV-K) modulates cytokine release and gene expression. Belshaw R, editor. PLoS One [Internet]. 2013;8:e70399. https:\/\/doi.org\/10.1371\/journal.pone.0070399.","DOI":"10.1371\/journal.pone.0070399"},{"key":"9012_CR32","doi-asserted-by":"publisher","unstructured":"Shaked R, Katz M, Cohen-Dvashi H, Diskin R. The prefusion structure of the HERV-K (HML-2) Env spike complex. Proceedings of the National Academy of Sciences [Internet]. 2025;122:e2505505122. https:\/\/doi.org\/10.1073\/pnas.2505505122.","DOI":"10.1073\/pnas.2505505122"},{"key":"9012_CR33","doi-asserted-by":"publisher","unstructured":"Shek J, Sun C, Wilson EM, Moadab F, Hastie KM, Rajamanickam RR, et al. Human endogenous retrovirus K (HERV-K) envelope structures in pre- and postfusion by cryo-EM. Sci Adv [Internet]. 2025;11. https:\/\/doi.org\/10.1126\/sciadv.ady8168.","DOI":"10.1126\/sciadv.ady8168"},{"key":"9012_CR34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/BF01665962","volume":"30","author":"M Nelson","year":"1989","unstructured":"Nelson M, Nelson DS, Cianciolo GJ, Snyderman R. Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products. Cancer Immunol Immunother [Internet]. 1989;30:113\u20138. https:\/\/doi.org\/10.1007\/BF01665962.","journal-title":"Cancer Immunol Immunother [Internet]"},{"key":"9012_CR35","doi-asserted-by":"publisher","first-page":"e4792","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, et al. <scp>UCSF ChimeraX<\/scp>: Tools for structure building and analysis. Protein Sci [Internet]. 2023;32:e4792. https:\/\/doi.org\/10.1002\/pro.4792.","journal-title":"Protein Sci [Internet]"},{"key":"9012_CR36","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1016\/j.vaccine.2018.07.075","volume":"36","author":"E Ragonnaud","year":"2018","unstructured":"Ragonnaud E, Schroedel S, Mariya S, Iskandriati D, Pamungkas J, Fougeroux C, et al. Replication deficient human adenovirus vector serotype 19a\/64: Immunogenicity in mice and female cynomolgus macaques. Vaccine [Internet]. 2018;36:6212\u201322. https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.075.","journal-title":"Vaccine [Internet]"},{"key":"9012_CR37","doi-asserted-by":"publisher","first-page":"e001046","DOI":"10.1136\/jitc-2020-001046","volume":"8","author":"JC Flickinger","year":"2020","unstructured":"Flickinger JC, Singh J, Carlson R, Leong E, Baybutt TR, Barton J, et al. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. J Immunother Cancer [Internet]. 2020;8:e001046. https:\/\/doi.org\/10.1136\/jitc-2020-001046.","journal-title":"J Immunother Cancer [Internet]"},{"key":"9012_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cell.2022.12.017","volume":"186","author":"X Liu","year":"2023","unstructured":"Liu X, Liu Z, Wu Z, Ren J, Fan Y, Sun L, et al. Resurrection of endogenous retroviruses during aging reinforces senescence. Cell [Internet]. 2023;186:287\u2013e30426. https:\/\/doi.org\/10.1016\/j.cell.2022.12.017.","journal-title":"Cell [Internet]"},{"key":"9012_CR39","doi-asserted-by":"publisher","first-page":"e0826232024","DOI":"10.1523\/JNEUROSCI.0826-23.2024","volume":"44","author":"PW Halcrow","year":"2024","unstructured":"Halcrow PW, Quansah DNK, Kumar N, Steiner JP, Nath A, Geiger JD. HERV-K (HML-2) Envelope Protein Induces Mitochondrial Depolarization and Neurotoxicity via Endolysosome Iron Dyshomostasis. J Neurosci [Internet] Soc Neurosci. 2024;44:e0826232024. https:\/\/doi.org\/10.1523\/JNEUROSCI.0826-23.2024. [cited 2026 May 8];.","journal-title":"J Neurosci [Internet] Soc Neurosci"},{"key":"9012_CR40","doi-asserted-by":"publisher","first-page":"1040792","DOI":"10.3389\/fmicb.2022.1040792","volume":"13","author":"S Chabukswar","year":"2022","unstructured":"Chabukswar S, Grandi N, Tramontano E. Prolonged activity of HERV-K(HML2) in Old World Monkeys accounts for recent integrations and novel recombinant variants. Front Microbiol [Internet]. 2022;13:1040792. https:\/\/doi.org\/10.3389\/fmicb.2022.1040792.","journal-title":"Front Microbiol [Internet]"},{"key":"9012_CR41","doi-asserted-by":"publisher","unstructured":"Marsh AK, Willer DO, Skokovets O, Iwajomo OH, Chan JK, MacDonald KS. Evaluation of cynomolgus macaque (Macaca fascicularis) endogenous retrovirus expression following simian immunodeficiency virus infection. Le Grand R, editor. PLoS One [Internet]. 2012;7:e40158. https:\/\/doi.org\/10.1371\/journal.pone.0040158.","DOI":"10.1371\/journal.pone.0040158"},{"key":"9012_CR42","doi-asserted-by":"publisher","unstructured":"Kraus B, Fischer K, B\u00fcchner SM, Wels WS, L\u00f6wer R, Sliva K, et al. Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system. Kozak CA, editor. PLoS One [Internet]. 2013;8:e72756. https:\/\/doi.org\/10.1371\/journal.pone.0072756.","DOI":"10.1371\/journal.pone.0072756"},{"key":"9012_CR43","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/FONC.2013.00246","volume":"3","author":"O Hohn","year":"2013","unstructured":"Hohn O, Hanke K, Bannert N. HERV-K(HML-2), the Best Preserved Family of HERVs: Endogenization, Expression, and Implications in Health and Disease. Front Oncol [Internet]. 2013;3:246. https:\/\/doi.org\/10.3389\/FONC.2013.00246. [cited 2026 Jun 3];.","journal-title":"Front Oncol [Internet]"},{"key":"9012_CR44","doi-asserted-by":"publisher","first-page":"e14046","DOI":"10.1200\/JCO.2019.37.15_SUPPL.E14046","volume":"37","author":"H Tao","year":"2019","unstructured":"Tao H, Hu Y. Correlation of HERVK with efficacy on anti-PD-1\/PD-L1 therapy in a pilot metagenomics study on Chinese advanced lung cancer patients. J Clin Oncol [Internet] Am Soc Clin Oncol. 2019;37:e14046\u201314046. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_SUPPL.E14046. [cited 2026 May 10];.","journal-title":"J Clin Oncol [Internet] Am Soc Clin Oncol"},{"key":"9012_CR45","doi-asserted-by":"publisher","unstructured":"Andersson A-MC, Schwerdtfeger M, Holst PJ. Virus-like-vaccines against HIV. Vaccines (Basel) [Internet]. 2018;6:10. https:\/\/doi.org\/10.3390\/vaccines6010010.","DOI":"10.3390\/vaccines6010010"},{"key":"9012_CR46","doi-asserted-by":"publisher","unstructured":"Morozov VA, Morozov AV, Semaan M, Denner J. Single mutations in the transmembrane envelope protein abrogate the immunosuppressive property of HIV-1. Retrovirology [Internet]. Retrovirology; 2012 [cited 2026 May 10];9. https:\/\/doi.org\/10.1186\/1742-4690-9-67.","DOI":"10.1186\/1742-4690-9-67"},{"key":"9012_CR47","doi-asserted-by":"publisher","first-page":"eabj3671","DOI":"10.1126\/sciadv.abj3671","volume":"8","author":"P Bonaventura","year":"2022","unstructured":"Bonaventura P, Alcazer V, Mutez V, Tonon L, Martin J, Chuvin N, et al. Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Sci Adv [Internet]. 2022;8:eabj3671. https:\/\/doi.org\/10.1126\/sciadv.abj3671.","journal-title":"Sci Adv [Internet]"},{"key":"9012_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2023.1275378","author":"A van de Vaccaro","year":"2023","unstructured":"van de Vaccaro A, Ramachandran M, Essand M, Dimberg A. Of mice and lymphoid aggregates: modeling tertiary lymphoid structures in cancer. Front Immunol [Internet] Front Immunol. 2023. https:\/\/doi.org\/10.3389\/FIMMU.2023.1275378. [cited 2026 Jun 3];14.","journal-title":"Front Immunol [Internet] Front Immunol"},{"key":"9012_CR49","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nat [Internet]. 2019;574:696\u2013701. https:\/\/doi.org\/10.1038\/s41586-019-1671-8.","journal-title":"Nat [Internet]"},{"key":"9012_CR50","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke L, Brunet M, Gu\u00e9gan J-P, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer [Internet]. 2021;2:794\u2013802. https:\/\/doi.org\/10.1038\/s43018-021-00232-6.","journal-title":"Nat Cancer [Internet]"},{"key":"9012_CR51","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","volume":"51","author":"R Zander","year":"2019","unstructured":"Zander R, Schauder D, Xin G, Nguyen C, Wu X, Zajac A, et al. CD4 + T Cell Help Is Required for the Formation of a Cytolytic CD8 + T Cell Subset that Protects against Chronic Infection and Cancer. Immun [Internet]. 2019;51:1028\u2013e10424. https:\/\/doi.org\/10.1016\/j.immuni.2019.10.009.","journal-title":"Immun [Internet]"},{"key":"9012_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS222212398","author":"VA Morozov","year":"2021","unstructured":"Morozov VA, Morozov AV. A Comprehensive Analysis of Human Endogenous Retroviruses HERV-K (HML.2) from Teratocarcinoma Cell Lines and Detection of Viral Cargo in Microvesicles. Int J Mol Sci [Internet] Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/IJMS222212398. [cited 2026 May 10];22.","journal-title":"Int J Mol Sci [Internet] Int J Mol Sci"},{"key":"9012_CR53","doi-asserted-by":"publisher","unstructured":"Sacha JB, Kim I-J, Chen L, Ullah JH, Goodwin DA, Simmons HA, et al. Vaccination with Cancer- and HIV Infection-associated Endogenous Retrotransposable Elements is Safe and Immunogenic. Volume 189. Oxford University Press (OUP); 2012;1467. [cited 2026 Aug 23];. https:\/\/doi.org\/10.4049\/JIMMUNOL.1200079.","DOI":"10.4049\/JIMMUNOL.1200079"},{"key":"9012_CR54","doi-asserted-by":"publisher","unstructured":"Eksmond U, Jenkins B, Merkenschlager J, Mothes W, Stoye JP, Kassiotis G. Mutation of the putative immunosuppressive domain of the retroviral envelope glycoprotein compromises infectivity. Sundquist WI, editor. J Virol [Internet]. 2017;91. https:\/\/doi.org\/10.1128\/JVI.01152-17.","DOI":"10.1128\/JVI.01152-17"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-09012-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-09012-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-09012-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:03:50Z","timestamp":1792796630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-09012-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9012"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-09012-1","relation":{"references":[{"id-type":"doi","id":"10.1186\/s13100-020-00224-w","asserted-by":"subject"},{"id-type":"doi","id":"10.64898\/2026.02.17.706328","asserted-by":"subject"},{"id-type":"doi","id":"10.1021\/ACSCHEMBIO.8B00061","asserted-by":"subject"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"With regards to the buffy coats from anonymous healthy donors, the study was conducted in accordance with the Declaration of Helsinki. Ethical review and approval were waived because this study only includes human biological material that was ethically obtained and anonymized according to Danish law by the blood bank at Rigshospitalet, Copenhagen. Danish law on ethics in scientific research \u201cBekendtg\u00f8relse af lov om videnskabsetisk behandling af sundhedsvidenskabelige forskningsprojekter og sundhedsdatavidenskabelige forskningsprojekter, LBK nr 1338 af 01\/09\/2020\u201d states no ethics approval will be needed when using purely anonymized human biological material (to \u00a7\u00a014 stk. 3). Patient consent was waived due to the material being ethically obtained according to Danish law by the blood bank at Rigshospitalet, Copenhagen, as purely anonymized human biological material. With regards to the human cancer biopsies from cancer patients referred to the Phase I Unit as part of the Copenhagen Prospective Personalized Oncology study (CoPPO, single-arm open-label study, NCT02290522), the study was conducted in accordance with the Declaration of Helsinki and approved by an institutional review board and the Regional Ethics Committee (Danish Ethical Committee, file number: 1300530). All patients provided signed informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PJH and CT are shareholders in HERVolution Therapeutics. AMCA, LN, ER, MPP, NS own warrants in HERVolution Therapeutics. PJH, LN, and CT are listed as inventors on the patent US12390522B2 (\u201cNucleic acids encoding human endogenous retrovirus K (HERV-K) envelope proteins containing modified immunosuppressive domains (ISD) and uses thereof\u201d) and patent US12263214B2 (\u201cVaccine for use in the prophylaxis and\/or treatment of a disease\u201d) related to this work. PJH, ER, LN, and AMCA are listed as inventors on the pending patent PCT\/EP2024\/060972 (\u201cImproved expression of surface-displayed antigens\u201d) related to this work. CT, SS, PJH, AMCA are listed as inventors on the pending patent PCT\/IB2024\/052851 (\u201cProduction of viral vectors\u201d) related to this work. Authors previously or currently employed by HERVolution Therapeutics as listed in author affiliations. HERVolution Therapeutics ApS provided financial support for the study and contributed to study design and manuscript review. The authors declare that these relationships have been disclosed and managed in accordance with institutional and journal policies.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1337"}}